CAL
AMPH icon

Capital Advisors Ltd’s Amphastar Pharmaceuticals AMPH Stock Holding History

Capital Advisors Ltd’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Sell
24
-146
-86% -$2.94K ﹤0.01% 1345
2026
Q1 		$3K Buy
170
+159
+1,445% +$3.89K ﹤0.01% 1024
2025
Q4 		$0 Buy
11
+3
+38% +$77 ﹤0.01% 1329
2025
Q3 		$0 Buy
+8
New +$207 ﹤0.01% 1336
2025
Q2 		– Sell
-75
Closed -$2K – 1320
2025
Q1 		$2K Sell
75
-15
-17% -$479 ﹤0.01% 1023
2024
Q4 		$3K Sell
90
-9
-9% -$412 ﹤0.01% 990
2024
Q3 		$5K Hold
99
– – ﹤0.01% 903
2024
Q2 		$4K Buy
99
+9
+10% +$373 ﹤0.01% 926
2024
Q1 		$4K Hold
90
– – ﹤0.01% 904
2023
Q4 		$6K Hold
90
– – ﹤0.01% 779
2023
Q3 		$4K Hold
90
– – ﹤0.01% 855
2023
Q2 		$5K Hold
90
– – ﹤0.01% 818
2023
Q1 		$3K Buy
90
+15
+20% +$492 ﹤0.01% 785
2022
Q4 		$2K Hold
75
– – ﹤0.01% 819
2022
Q3 		$2K Buy
+75
New +$2.45K ﹤0.01% 801

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital Advisors Ltd's AMPH Position: Q2 2026 in Review

Capital Advisors Ltd reduced its Amphastar Pharmaceuticals (AMPH) stake by 86% in Q2 2026, selling an estimated $2.94K and leaving 24 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1345.

Capital Advisors Ltd first reported a position in AMPH in Q3 2022 and has held it in 15 quarters since. The position peaked at $6K in Q4 2023. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Capital Advisors Ltd held 24 shares of Amphastar Pharmaceuticals worth $0 as of Q2 2026.
  • Capital Advisors Ltd sold 146 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $2.94K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1345 holding.
  • Capital Advisors Ltd first reported a position in Amphastar Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Capital Advisors Ltd's Amphastar Pharmaceuticals position peaked at $6K in Q4 2023.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.